Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
TENAX THERAPEUTICS, INC. entered into Securities Purchase Agreement with certain purchasers valued at Gross proceeds of approximately $15.6 million (effective 2023-02-03).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain purchasers
- Value
- Gross proceeds of approximately $15.6 million
- Effective
- 2023-02-03
Exact text from the filing
On February 3, 2023, Tenax Therapeutics, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 6,959,444 shares of its common stock, par value $0.0001 per share (“Common Stock”) and pre-funded warrants to purchase an aggregate of 1,707,222 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying warrants to purchase up to an aggregate of 17,333,332 shares of its Common Stock (the “Common Warrants”) at a combined offering price of $1.80 per share of Common Stock and associated Common Warrant, or $1.799 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.6 million.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
TENAX THERAPEUTICS, INC. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at Cash fee of 7% of aggregate gross proceeds raised in the Public Offering (effective 2023-02-03).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Roth Capital Partners, LLC
- Value
- Cash fee of 7% of aggregate gross proceeds raised in the Public Offering
- Effective
- 2023-02-03
Exact text from the filing
(the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with certain purchasers for the purchase and sale, in a registered public offering by the Company (the “Public Offering”), of (i) an aggregate of 6,959,444 shares of its common stock, par value $0.0001 per share (“Common Stock”) and pre-funded warrants to purchase an aggregate of 1,707,222 shares of Common Stock (the “Pre-Funded Warrants”) and (ii) accompanying warrants to purchase up to an aggregate of 17,333,332 shares of its Common Stock (the “Common Warrants”) at a combined offering price of $1.80 per share of Common Stock and associated Common Warrant, or $1.799 per Pre-Funded Warrant and associated Common Warrant, resulting in gross proceeds of approximately $15.6 million.
View on SEC.gov